Renal functional outcomes after surgery for renal cortical tumors by Lascano, Danny et al.
Lascano et al.                                                                                                               Renal function after nephrectomy                                                                                       
Journal of Kidney Cancer and VHL 2015; 2(2):45-54             http://jkcvhl.com  
 
Journal of Kidney Cancer and VHL 2015; 2(2):45-54 
DOI: http://dx.doi.org/10.15586/jkcvhl.2015.26 
 
Review Article 
 
Renal functional outcomes after surgery for renal 
cortical tumors 
 
Danny Lascano, Julia B. Finkelstein, G. Joel DeCastro, James M. 
McKiernan 
 
Herbert Irving Cancer Center, Columbia University College of Physicians and Surgeons, Department of 
Urology, New York, NY, USA 
 
Abstract 
 
Historically, radical nephrectomy represented the gold standard for the treatment of small 
(≤ 4cm) as well as larger renal masses.  Recently, for small renal masses, the risk of ensuing 
chronic kidney disease and end stage renal disease has largely favored nephron-sparing 
surgical techniques, mainly partial nephrectomy. In this review, we surveyed the literature 
on renal functional outcomes after partial nephrectomy for renal tumors. The largest 
randomized control trial comparing radical and partial nephrectomy failed to show a 
survival benefit for partial nephrectomy. With regards to overall survival, surgically induced 
chronic kidney disease (GFR < 60 ml/min/ 1.73m2) caused by nephrectomy might not be as 
deleterious as medically induced chronic kidney disease. In evaluating patients who 
underwent donor nephrectomy, transplant literature further validates that surgically 
induced reductions in GFR may not affect patient survival, unlike medically induced GFR 
declines.  Yet, because patients who present with a renal mass tend to be elderly with 
multiple comorbidities, many develop a mixed picture of medically, and surgically-induced 
renal disease after extirpative renal surgery.  In this population, we believe that nephron 
sparing surgery optimizes oncological control while protecting renal function. Copyright: The 
Authors. 
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Introduction 
 
Renal lesions can be classified as 
malignant, benign, or inflammatory. 
Inflammatory renal lesions may mimic 
malignant renal lesions on imaging and 
include infection, inflammation, or trauma 
induced lesions (1).  Of the non-
inflammatory cases, benign masses 
compose approximately 13% of newly 
diagnosed lesions such as oncocytomas 
and angiomyolipomas; the rest renal cell 
carcinoma (2).  Renal cell carcinoma (RCC) 
accounts for 3.8% of all cases of adult 
malignant neoplasms. It typically presents 
in the sixth and seventh decades of life.  
RCC of clear cell histology is the most 
common, followed by papillary and 
chromophobe subtypes (2). Overall, the 
incidence of RCC has increased in the last 
three decades with an estimated 63,920 
cases and 13,860 deaths (3).  The advent of 
improved imaging techniques such as 
computer tomography (CT) and magnetic 
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resonance imaging (MRI) has partially 
driven this rising incidence, as clinicians 
can now detect pre-symptomatic renal 
tumors incidentally (3, 4). Accordingly, 
small renal masses (SRM) that are less 
than or equal to 4 cm are being detected 
more frequently. In the prior decade, the 
average renal tumor size decreased from 
6.7 cm to 5.9 cm (5). 
 
In part, imaging can assist in 
differentiating renal masses of unknown 
malignant potential.  For instance, benign 
lesions like angiomyolipomas can be 
identified by the presence of macroscopic 
fat.  CT or MRI scan with intravenous 
contrast administration can help 
distinguish those renal masses that need 
further evaluation.  For a renal mass to be 
considered malignant, it should enhance 
with administration of contrast. However, 
10-20% of small, solid CT-enhancing renal 
masses are found to be benign after 
surgical removal (6).  In particular, 
differentiating a benign renal cyst and a 
cystic RCC by imaging is difficult. 
 
In terms of the size distribution of RCC, 
35% of tumors are < 4 cm, 33% are 
between 4 and 7 cm, and 32% are > 7 cm 
(5).  Larger masses are increasingly 
correlated with malignancy and worse 
outcomes (7). The size of the renal mass, 
tumor risk profile, and clinical symptoms 
are all significant prognostic factors.  
However, pathologic stage is the most 
important prognostic factor. Patient-related 
factors like comorbidities and frailty are 
also influential in determining appropriate 
management. 
 
In the management of a renal mass the 
most important predictors of post-operative 
GFR besides pre-operative GFR are both 
residual functioning parenchyma and 
ischemia time (8).  Chronic kidney disease 
(CKD) in general is defined as an estimated 
glomerular filtration rate (GFR) of less than 
60 mL/min/1.73m2 for over 90 days (9).  
The different stages of CKD are categorized 
as shown in Table 1. End stage renal 
disease (ESRD) is defined as GFR less than 
15 mL/min/1.73m2 and requires renal 
replacement therapy such as hemodialysis. 
 As we progress beyond the Halstedian era 
of radical extirpative approaches in 
oncologic surgery and move into the era of 
minimally invasive surgery, a series of 
questions arise in the management of renal 
masses.  One specific question that we will 
address is whether sparing nephrons 
impacts mortality. 
 
Management Approaches 
 
As stated above, localized SRMs have 
increased in incidence and now are a fairly 
common clinical situation.  Historically, 
radical nephrectomy represented the gold 
standard for the treatment of all renal 
masses.  The first documented radical 
nephrectomy was completed for the 
treatment of renal cell carcinoma in 1963 
(10).  It still represents the standard of care 
in non-localized cases and for renal masses 
of unknown malignant potential in 30% of 
cases (11).  However, practices have 
changed dramatically in the last two 
decades.  It has been recognized that SRMs 
have broad heterogeneity in tumor biology 
and several management strategies are now 
offered, including radical nephrectomy 
(RN), partial nephrectomy (PN), thermal 
ablation (TA) as well as active surveillance 
(AS).  Moreover, for treating SRMs, the risk 
of ensuing CKD and ESRD requiring renal 
replacement therapy has largely favored 
nephron-sparing surgery. 
 
PN involves complete but localized 
resection of the tumor, while maintaining 
the most amount of normal parenchyma 
possible.  For the surgical management of 
SRMs of ≤4 cm, PN has become standard of 
care. Some even suggest its application be 
expanded to masses up to 7 cm in size, 
given their 20-30% likelihood of benign 
pathology (12). With regards to approach, 
both laparoscopic and robotic PNs have 
been shown to have good outcomes with 
short recovery time, acceptable ischemia 
time, and less morbidity than open PN (13, 
14).   Robotic technology is generally 
preferred for PN, given the technical 
limitations of laparoscopic surgery, and the 
literature does support its use for moderate 
to complex renal masses given the 
decreased conversion rate to RN for robotic 
PN in comparison to laparoscopic PN (15).  
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Table 1.  Definitions of CKD stages based on GFR 
Chronic Kidney 
Disease Stage 
Estimated GFR 
(ml/min/ 1.73m2) 
I ≥ 90 
II 60 – 89 
III 30 – 59 
IV 15 – 29 
 
 
Thermal ablative treatments such as renal 
cryoablation (CA) and radiofrequency 
ablation (RFA) have materialized as 
alternative nephron-sparing therapies for 
patients with localized SRMs. Both 
techniques can be initiated percutaneously 
or via laparoscopic exposure. Some report 
reduced morbidity with this treatment but 
the long-term oncological control has not 
been well established, with a greater 
incidence of local recurrence reported for 
these techniques than for surgical 
approaches. RFA is reported to have a 
likelihood of tumor recurrence of 12.9% 
and risk of metastasis of 2.5%, even within 
a well-selected population (16). Meanwhile, 
a meta-analysis by Kunkle and Uzzo 
looking at CA showed a likelihood of tumor 
recurrence of 5.2% and risk of metastasis 
of 1% (16). These TA recurrences may be 
salvageable with repeat ablation, although 
some need traditional surgery. In the latter 
case, radical or partial nephrectomy may 
be impossible to perform secondary to the 
widespread fibrotic reaction caused by the 
TA (17). 
 
However, the same population that may 
benefit from ablative treatment of SRMs, 
may benefit from inclusion into an active 
surveillance with delayed intervention 
protocol (18). Bosniak et al showed that 
renal tumors grow at slow and variable 
rates of up to 1.1 cm per year with a 
median growth rate of 0.36 cm per year 
(19).  A more recent study by Crispen and 
colleagues that followed patients with a 
localized, enhancing renal mass revealed 
that absolute growth rate following 
detection of the tumor was 0.039 cm/year 
(20). In another study observing 209 
patients with SRMs and limited life 
expectancy for a mean of 28 months, local 
progression occurred in 12% and 2 
patients (1.1%) developed metastases (21). 
Besides the slow growth rate and limited 
progression of most SRMs, the risk of 
competing causes of death and of 
intervention may also favor AS in this 
population. A study by Hollingsworth et al. 
evaluating patients’ survival 5 years after 
surgical treatment of RCC showed that one 
third of the elderly may die from their 
comorbidities (22). Therefore, elderly 
patients or patients of poor surgical risk 
with a small, solid, well-defined renal lesion 
may be managed with active surveillance, 
involving serial renal imaging biannually or 
annually, and delayed intervention when 
necessary. 
 
Renal function after TA techniques and 
on AS 
 
Some literature endorses superior renal 
function with TA over conventional surgery. 
A study by Woldu et al. comparing renal 
parenchymal loss between CA, RFA, and 
PN showed that TA was associated with 
less renal parenchymal loss (23).   In 
another retrospective comparison of 
patients with a suspicious renal mass of 
less than 5 cm, Lucas et al revealed that 
RFA has a freedom of CKD of 95.2% in 
comparison to PN at 70.7% and RN at 
39.9% (24).  In a European study 
evaluating cryoablation, renal function was 
relatively well conserved, as prior to 
treatment GFR was 66 mL/min and it was 
60 mL/min post-CA (25). In addition, those 
with existing CKD experienced no change 
in GFR. 
 
Limited data exists on renal function while 
on active surveillance.  In a recent analysis 
from the Delayed Intervention and 
Surveillance for Small Renal Masses 
Registry (DISSRM), in a group of 64 
patients on AS with a renal mass of < 4 cm 
and a median baseline GFR of 70.3, 64% of 
patients experienced a decline in GFR at a 
yearly rate of 1.82 mL/min/1.73m2.  This 
GFR decline is higher than would be 
expected from aging alone. Furthermore, 
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24% of patients in the study experienced 
upstaging in their CKD classification (26). 
However, given the multiple comorbidities 
and advanced age of many patients who 
present with a SRM, AS remains an 
attractive alternative that warrants further 
investigation. 
 
Renal Function after Extirpative Surgery 
 
Most of the literature has focused on renal 
function after radical and partial 
nephrectomy.  A main concern with 
performing RN is reduction of GFR and 
ultimately requiring dialysis. In a 
retrospective study of 290 patients with 
SRMs < 4 cm, McKiernan, et al. showed 
that 5-year freedom from chronic renal 
insufficiency, which was defined as a 
creatinine of > 2 mg/mL, was 100% in the 
PN group and 84.6%% in the RN group 
(27).  In another retrospective study, 
Huang and colleagues revealed that 65% of 
RN patients, in comparison to 20% of the 
PN patients, had grade III CKD (GFR < 60 
ml/min/1.73m2) at 3-year follow-up (28). 
Severe CKD was also more likely after RN 
than PN, with an incidence of 36% versus 
5% respectively.  In other studies, when the 
tumor mass and pre-operative GFR was 
taken into account the loss of kidney 
function remained higher in RN than PN 
(29, 30). 
 
Furthermore, a retrospective study by 
Kaushik and colleagues evaluated patients 
undergoing RN or PN for a benign renal 
mass, which eliminates the confounder of 
malignancy in the survival equation.  They 
demonstrated that overall survival at ten 
years was 69% for RN and 80% for PN, with 
a decreased risk of CKD in the PN group in 
comparison to RN group (31).  This alludes 
to a possible superiority of NSS over RN 
with regards to renal function.  Finally, one 
of the largest and most recent studies 
evaluating 2068 patients with a 5-year 
follow up period showed that renal function 
after RN led to new onset CKD stage III in 
36.1% of patients and new onset CKD stage 
IV in 3.4% of patients (32). 
 
Ischemia is the major concern with PN, as 
this may induce tissue necrosis and 
irreversible damage to the functioning renal 
parenchyma. This is especially pronounced 
in cases where ischemia is more than 40 
minutes, although even in shorter intervals 
there is some evidence of parenchyma 
atrophy (33).  However, whether reducing 
ischemia time leads to a reduction in 
nephron damage as measured by GFR 
function is unclear. A recent meta-analysis 
by Liu et al. revealed that there was a 
higher odds of GFR decline in patients who 
undergo on-clamp partial nephrectomy in 
comparison to off-clamp partial 
nephrectomy without ischemia (34).  Yet, 
no study thus far has prospectively looked 
at the post-operative renal function of off-
clamp versus on-clamp with ischemia. 
 
Nevertheless, the largest randomized 
control trial comparing RN and PN failed to 
show a survival benefit of NSS.  In the 
EORTC 30904 trial, Van Poppel and 
colleagues demonstrated that 85.7% of 
patients undergoing RN experience a 
reduction in their GFR to below 60 
ml/min/ 1.73m2 in comparison to only 
64.7% of the group undergoing PN (35, 36).  
Despite this diminished impact on renal 
function, the PN group did not experience 
improved overall mortality outcomes.  In 
other words, the higher incidence of de-
novo CKD post-surgery in the RN cohort 
did not portend greater overall mortality. 
Since the European population has a lower 
level of comorbidities in comparison to an 
American population, this study was more 
accurately evaluating the impact of surgical 
CKD (CKD-S). Perhaps, with regards to 
overall survival, CKD-S caused by 
nephrectomy might not be as deleterious as 
medical CKD (CKD-M). 
 
Defining surgical versus medical chronic 
kidney disease 
 
Traditionally, literature on CKD has 
focused on medical CKD-M, which affects 
over 19 million Americans (37).  This type 
of CKD stems from microscopic damage at 
the level of nephrons, either from 
hypertension, diabetes, or other medical 
causes. CKD-M increases the risk of death, 
mainly from adverse cardiovascular events 
(38).   In addition, CKD has been 
associated with coagulopathies, anemia, 
left ventricular hypertrophy, arterial 
calcification, and other pathophysiology 
(39-43). Most importantly, CKD places 
patients at risk for 
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ESRD and its accompanying high rate of 
mortality, morbidity, and cost to the 
healthcare system (44). 
 
Only the urological and transplant 
literature distinguish surgical CKD-S from 
medical causes of renal dysfunction. CKD-
S as defined by Lane et al is when patients 
develop chronic renal insufficiency after 
nephrectomy without an underlying 
medical cause for their renal disease (45).  
Because patients who present with a renal 
mass tend to be elderly with multiple 
comorbidities, many develop a mixed 
picture of CKD-M and CKD-S after 
extirpative renal surgery (46).  This was 
confirmed by the landmark study from 
Memorial Sloan Kettering Cancer Center 
discussed above (45).  Twenty-six percent 
of 662 patients with a small solitary tumor 
had preexisting grade III CKD.  
Furthermore, in a retrospective study of 
4180 patients undergoing nephrectomy of 
any type, Lane and colleagues showed that 
the annual decline in GFR for patients with 
existing CKD-M who develop CKD-M/S was 
4.7% after surgery (45).  On the other 
hand, for those without pre-existing CKD 
who developed CKD-S, the decline was only 
0.7% in GFR. Post-operative GFR was not a 
significant predictor of survival after 6.6-
year median follow-up for patients with 
CKD-S but did predict survival in those 
with CKD-M/S with worse survival for 
those with lower post-operative GFR.  This 
data was supported by another study from 
the same group in which CKD-M/S and 
CKD-S groups were compared to those with 
CKD-M who did not undergo surgery.  
Demirjian and colleagues showed that the 
CKD-S group had better overall survival 
and less of a decline in renal function (47).  
This validates that CKD-S is a separate 
entity from CKD-M and mixed CKD-M/S. It 
follows that urological experience with 
CKD-S may parallel that of the donor 
nephrectomy population analyzed in the 
transplant literature. 
 
The pathophysiology of surgical CKD 
and review of the transplant literature 
 
The hypothesized mechanism for renal 
injury after renal transplant in the 
remaining donor’s kidney is renal 
hyperfiltration possibly followed or 
preceded by renal hypertrophy.  Animal 
models as well as research on human renal 
tissue show that after nephron loss there is 
a concomitant increase in the GFR of the 
remaining kidney (48, 49). It is 
hypothesized that given the decline in the 
number of nephrons, the remaining kidney 
tissue hypertrophies leading to increased 
renal volume due to the increase of renal 
plasma flow and increased intraglomerular 
pressure (50).  Eventually the nephrons 
become unable to compensate with the 
increased load leading to nephron 
exhaustion (51). Brenner and colleagues 
propose that this increased hyperfiltration 
and the decrease in nephron number may 
explain why some patients develop renal 
injury, hypertension, proteinuria and other 
kidney related diseases (52). 
 
However, since not all patients develop this 
adverse pathology or a significant GFR 
decline after surgery, there must be a 
further explanation. There may be a 
threshold below which a kidney can 
tolerate further strain— that is a nephron 
reserve defined by the nephron surface 
area and mass (53).  Once this reserve is 
overwhelmed, perhaps damage becomes 
unmanageable with ensuing kidney 
function decline. The evidence for this 
theory largely stems from animal studies, 
retrospective papers, and one prospective 
study.  Brenner et al in a rat model showed 
that after thermal renal ablation of a renal 
mass the remaining nephrons experience 
hypertrophy on pathology (54).  From this 
experiment, it was hypothesized that the 
increase in GFR with concomitant low 
nephron reserve leads to increased 
intraglomerular hypertension and 
eventually albuminuria and kidney 
function decline in humans also (55).  This 
increase in GFR measured by higher than 
normal rates has been shown to occur in 
patients with unilateral renal agenesis, 
congenitally reduced nephron numbers, 
and acquired reduction in renal mass (56-
58).  Elsherbiny and colleagues suggest 
that increased renal plasma flow may 
induce renal damage that eventually leads 
to glomerulosclerosis, GFR decline, and 
hypertension (59).  Their study looked at 
nephron size using biopsies obtained from 
donor kidneys during transplantation and 
showed that indeed some of these predicted 
structural characteristics of hyperfiltration 
are seen in humans pre-operatively in 
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patients with high GFR at time of their 
biopsy.  Moreover, larger glomerular 
volume, increased mean profile tubular 
area, and lower glomerular density were all 
associated with risk factors for CKD (59). 
 
To be a kidney donor, stringent criteria 
must be met including having a high 
baseline GFR and minimal to no 
comorbidities.  The transplant literature 
has analyzed survival in these patients who 
have donated their kidney.  This population 
may most accurately reflect CKD-S. In a 
large cross-sectional study among older 
kidney donors, Fehrman-Ekholm et al 
showed that 10% developed proteinuria 
and half of the male donors developed 
hypertension (60).  Both of these results 
are higher than expected in the general 
non-donor population.  Overall, 72% of the 
group had a decline in their average 
estimated GFR based on their age.  Out of 
402 donors who lived to follow up, only 5 
patients developed a GFR of less than 30 
and 1 patient ultimately required dialysis. 
Ibrahim and colleagues evaluated the 
incidence of ESRD after unilateral donor 
nephrectomy and found that 14.5% of their 
cohort developed CKD with a GFR of less 
than 60 ml/min/ 1.73m2 at most recent 
follow up.  They also noted a higher than 
expected incidence of hypertension and 
albuminuria, but overall survival did not 
differ between kidney donors and matched 
non-donors (61).  This further suggests 
that surgically induced reductions in GFR 
may not affect patient survival, unlike 
medically induced declines.  In addition, 
this data may elucidate why the EORTC 
30904 failed to show a survival benefit for 
PN despite the increased CKD in the RN 
cohort. 
 
Future directions 
 
Other than renal biopsy, there is currently 
no mechanism that predicts what the 
pathology of a renal mass will be.  Both 
advances in imaging and development of 
biomarkers that can be correlated with 
histology are necessary to help differentiate 
renal masses. This would prevent the 
surgical removal of a substantial number of 
tumors that are actually benign or of low 
malignant potential. It could also guide in 
selecting the appropriate management 
strategy based on tumor risk profile along 
with patient characteristics. Improving our 
assessment of kidney function beyond GFR 
would also assist in more aptly risk 
stratifying patients. 
 
Furthermore, research should be dedicated 
to resolving the question of whether RN is 
superior to PN in terms of overall survival 
in a more heterogeneous population.  
Ideally, another randomized controlled trial 
should be completed.  Along these lines, 
further evaluation of the alternative 
nephron-sparing techniques and their 
oncological as well as renal functional 
impact is necessary.  Studies with longer-
term follow up are needed for thermal 
ablation and active surveillance. 
 
Finally, a better grasp of the 
pathophysiology of surgically induced 
chronic kidney disease is warranted.  
Further understanding of the mixed state 
of medically and surgically induced CKD in 
the aging population is also necessary.  
While surgically induced CKD seems to be 
a separate entity with different mortality 
rates, the literature currently makes little 
or no distinction. 
 
Conclusions 
 
In patients with small renal masses, a 
solitary kidney, multiple comorbidities, or 
those with multiple tumors, nephron-
sparing surgery, mainly partial 
nephrectomy, is considered standard of 
care.  Thermal ablative treatments have 
materialized as alternative nephron-sparing 
therapies for patients with localized small 
renal masses. These therapies have been 
associated with higher recurrence rates 
and have unknown long-term oncological 
outcomes. Therefore, of the nephron-
sparing treatments, we would argue that 
partial nephrectomy optimizes oncological 
control while protecting renal function. 
 
Nonetheless, a large randomized controlled 
trial comparing radical and partial 
nephrectomy failed to show a survival 
benefit of nephron sparing surgery.  This 
finding as well as data from the kidney 
donor population indicates that surgically 
induced renal dysfunction may not warrant 
as much concern or vigilance as medically 
induced renal disease. Further 
investigation and randomized trials are 
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warranted to help elucidate the benefits of 
PN in comparison to RN as well to explore 
the pathophysiology and impact of 
medically versus surgically induced chronic 
kidney disease. 
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